nSTRIDE APS is an autologous, single injection to treat osteoarthritis (OA) of the knee.It can help to provide pain relief and improve knee function while targeting OA inflammation at the source by preserving cartilage.,
A single injection has shown a 70% improvement in pain associated with OA for two years (Figure 1).
Patients that crossed-over from Hyaluronic Acid (HA) to nSTRIDE APS experienced a significant pain reduction at one-year compared to patients that switched from nSTRIDE APS to HA.
A clinical study showed a positive correlation between APS/WBC concentration and early pain relief, with improved WOMAC pain scores at six months post-injection and nSTRIDE APS demonstrated significant pain improvement compared to saline at one-year using a novel responder criteria.
Effusions (≥5 mL) significantly decreased nine months after one injection.
64% of patients avoided additional knee treatments five years post-injection.
Significant improvements in pain, function, stiffness, and total scores at one-year.
Patients reported improvement in knee osteoarthritis symptoms one year after injection'
Demonstrated pain relief from osteoarthritis of the knee for up to two years with a single injection.
nSTRIDE APS can reduce cartilage degeneration by introducing anti-inflammatory cytokines (IL-1ra, sIL-1RII, sTNF-RI, sTNF-RII) that:
Block cartilage-degrading enzyme MMP-13.
Reduce cartilage breakdown debris in the joint.
Decrease pro-inflammatory cytokines in the synovium.' ' '
High levels of anti-inflammatory cytokines and anabolic growth factors help halt OA progression and restore balance. '
